Federico Cappuzzo

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (181)

• Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
  Expert Review of Clinical Pharmacology 2016 DOI: 10.1586/17512433.2016.1122518
  +Save
• EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center
  Oncology Reports 2016 DOI: 10.3892/or.2016.4874
  +Save
• Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
  Lung Cancer 2016 DOI: 10.1016/j.lungcan.2016.06.008
  +Save
• Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations
  Journal of Thoracic Oncology 2016 DOI: 10.1016/j.jtho.2015.12.107
  +Save
• Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: Results from the European EUHER2 cohort
  Annals of Oncology 2016 DOI: 10.1093/annonc/mdv573
  +Save
• Management of NSCLC Disease Progression after First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
  Drugs 2016 DOI: 10.1007/s40265-016-0578-z
  +Save
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  Therapeutic Advances in Medical Oncology 2016 DOI: 10.1177/1758834016631531
  +Save
• Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy
  Lung Cancer 2016 DOI: 10.1016/j.lungcan.2016.01.007
  +Save
• Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
  Annals of Oncology 2016 DOI: 10.1093/annonc/mdw174
  +Save
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial
  The Lancet Oncology 2015 DOI: 10.1016/S1470-2045(15)70054-9
  +Save